Macrocyclic PAD4 Inhibitors for Selective Immunosuppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for PAD4-mediated disorders, such as rheumatoid arthritis, systemic lupus erythematosus, and various inflammatory and cancerous conditions, lack effective inhibitors that can selectively target PAD4 without affecting other peptidylarginine deiminases, leading to incomplete therapeutic responses and potential off-target effects.
Innovation Solution
Development of compounds of Formula (I) that act as selective inhibitors of PAD4, offering potential treatments for PAD4-mediated disorders by modulating citrullination levels and epigenetic regulation, thereby reducing inflammation and pathological neutrophil activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for PAD4-mediated disorders are used, then therapeutic coverage is provided, but selectivity for PAD4 is insufficient leading to off-target effects
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular features (hydrophobic groups, hydrogen bonding capabilities, specific ring structures) that create localized interactions with PAD4's active site. This ensures the inhibitor binds selectively to PAD4's unique structural characteristics while leaving other peptidylarginine deiminases unaffected, thereby achieving therapeutic efficacy without off-target effects.
Solution Approach 2:
The patent employs parameter changes by systematically varying key molecular parameters of the inhibitor compounds including hydrophobicity (through different hydrocarbon chains and aromatic groups), hydrogen bonding capacity (through amide, carbonyl, and hydroxyl groups), and steric configuration (through cyclic and acyclic structures). These parameter optimizations enable selective binding to PAD4 while maintaining therapeutic effectiveness.
2Object-affected harmful factors
If selective PAD4 inhibitors are developed, then off-target effects are reduced, but therapeutic response completeness may be compromised
Solution Approach 1:
The patent achieves universality by designing inhibitors that can address multiple PAD4-mediated pathological conditions through a single mechanism of action. The compounds are applicable to rheumatoid arthritis, systemic lupus erythematosus, vasculitis, ulcerative colitis, and other inflammatory diseases, providing comprehensive therapeutic response while maintaining selectivity for PAD4 across different disease contexts.
Solution Approach 2:
The patent applies partial action by using inhibitors that selectively target PAD4's citrullination activity without completely abolishing all peptidylarginine deiminase functions. This partial inhibition is sufficient to reduce pathological citrullination and inflammation while preserving necessary physiological functions, thereby maintaining complete therapeutic response with enhanced selectivity.
Data Source
AI summary
The present invention provides compounds of Formula (I) useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders, (I) wherein ring A, A1, A2, A3, A4, Q, R1, R2, R3, R4, R5, and R6 along with other variables are as defined herein.